Cydar Medical has announced a strategic collaboration with Medtronic, a global leader in healthcare technology. Under the pilot arrangement, Cydar’s EV Maps software will be introduced to up to 40 new global sites, combining Cydar’s augmented intelligence technology with Medtronic’s services and case support, with the goal of improving patient care.
The Cydar EV Maps software harnesses the latest in cloud GPU computing, computer vision and machine learning technology to advance surgical visualization and decision-making in theatre and across the care pathway. This enables clinicians to create detailed patient-specific 3D maps for procedure planning, image-guided navigation, and post-operative review, resulting in less radiation exposure to the patient and the clinical team, reduced procedure time, and increased delivery confidence.1-3 This pilot program will also inform the future development of predictive analytics to support procedure planning, by assessing factors such as the risk of endoleaks, sac regression probability and more.
Medtronic is the first medical technology company to enter a public strategic collaboration in digital endovascular technology to advance aortic patient treatment decisions. The collaboration is part of Medtronic’s ongoing commitment to innovation in aortic care for physicians and their patients.
“Medtronic aims to revolutionize endovascular aortic treatment with digital solutions with this phased approach. By collecting data across the patient journey—before, during and after procedure—our goal is to provide analytic support to make our endovascular stent grafts ‘smart’.” said Carolyn Sleeth, VP, General Manager, Aortic.
“By collaborating with Medtronic to bring our Cydar EV Maps solution to up to 40 new hospital sites, we are a step closer to achieving our mission to ensure every image-guided endovascular procedure goes exactly as planned,” said Paul Mussenden, CEO of Cydar.
Cydar EV Maps is currently available in the EU, UK and US. It is certified Software-as-a-Medical Device with an EU CE mark and U.S. FDA 510(k) clearance.
1 Maurel B, Martin‑Gonzalez T, Chong D, et al. A prospective observational trial of fusion imaging in infrarenal aneurysms. J Vasc Surg. 2018;68:1706‑1713.
2 Shortell C, Veith Symposium New York, 2017
3 Cydar Medical data on file.
Source: Cydar Medical